Literature DB >> 13989148

A clinical trial of nalidixic acid (Negram, WIN. 18,320) in thirty-three patients with urinary infections treated in general practice.

D A SLADE.   

Abstract

Entities:  

Keywords:  ANTI-INFECTIVE AGENTS; ESCHERICHIA COLI INFECTIONS; NAPHTHYRIDINES; PROTEUS INFECTIONS; URINARY TRACT INFECTIONS

Mesh:

Substances:

Year:  1963        PMID: 13989148     DOI: 10.1111/j.1464-410x.1963.tb02604.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


× No keyword cloud information.
  6 in total

1.  A COMPARATIVE STUDY OF THE LEVELS OF NALIDIXIC ACID IN PLASMA AND URINE AND ITS ANTIBACTERIAL ACTIVITY IN URINARY INFECTIONS OF PARAPLEGICS.

Authors:  N O GIBBON; J G BENSTEAD; G C MISRA
Journal:  Postgrad Med J       Date:  1965-08       Impact factor: 2.401

2.  A CLINICAL TRIAL WITH NALIDIXIC ACID ON 22 ACUTE AND CHRONIC URINARY TRACT INFECTIONS WITH FOLLOW-UP FOR 1-5 MONTHS.

Authors:  G C MISRA; M C WILLCOX
Journal:  Postgrad Med J       Date:  1965-08       Impact factor: 2.401

3.  Experience with nalidixic Acid in the treatment of urinary tract infections of children.

Authors:  S Autio; P Mäkelä; R Sunila
Journal:  Arch Dis Child       Date:  1966-08       Impact factor: 3.791

Review 4.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 5.  Transferable Mechanisms of Quinolone Resistance from 1998 Onward.

Authors:  Joaquim Ruiz
Journal:  Clin Microbiol Rev       Date:  2019-08-14       Impact factor: 26.132

6.  NALIDIXIC ACID (NEGGRAM) IN THE TREATMENT OF URINARY INFECTIONS.

Authors:  L REESE
Journal:  Can Med Assoc J       Date:  1965-02-20       Impact factor: 8.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.